-+ 0.00%
-+ 0.00%
-+ 0.00%

Aytu BioPharma Q1 2025 GAAP EPS $(0.20) Beats $(0.34) Estimate, Sales $16.574M Beat $13.768M Estimate

Benzinga·11/13/2024 21:13:39
Listen to the news
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.34) by 41.18 percent. The company reported quarterly sales of $16.574 million which beat the analyst consensus estimate of $13.768 million by 20.38 percent. This is a 25.00 percent decrease over sales of $22.099 million the same period last year.